World's Best Scientists 2026 revealed!
Christoph C. Zielinski

Christoph C. Zielinski

D-Index & Metrics

Medicine

D-Index
104
Citations
40847
World Ranking
7035
National Ranking
34

Christoph C. Zielinski publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christoph C. Zielinski sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 905 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christoph C. Zielinski D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christoph C. Zielinski sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christoph C. Zielinski is affiliated with the Medical University of Vienna in Austria and has contributed extensively to the field of medicine, particularly focusing on oncology. Their research spans over 143 publications, with a significant emphasis on oncology, represented by 67 publications within this subfield.

The scientist's work covers several specialized subfields, including pulmonary and respiratory medicine, immunology, economics and econometrics, and radiology, nuclear medicine, and imaging. This multidisciplinary approach supports a comprehensive exploration of cancer and associated treatments.

Among the main research topics Christoph C. Zielinski has explored are:

  • Advanced Breast Cancer Therapies
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Economic and Financial Impacts of Cancer
  • Colorectal Cancer Treatments and Studies

Their publications are frequently found in well-known oncology-related journals. The most common venues for their work include:

  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • European Journal of Cancer
  • Journal of Clinical Oncology

Some of the recent papers authored or co-authored by Christoph C. Zielinski are:

  • Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial, 2023, Nature Medicine
  • Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders, 2021, Cancer Discovery
  • Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL, 2020, Annals of Oncology
  • Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials, 2020, Research and Practice in Thrombosis and Haemostasis
  • Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring, 2021, ESMO Open

Collaboration is a key component of their research efforts. Frequent co-authors include:

  • Ursula Wiedermann
  • Erika Garner-Spitzer
  • Michael Kundi
  • Miguel Gil-Gil
  • Montserrat Muñoz

Best Publications

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim

  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

    M. S. Aapro;J. Bohlius;David Cameron;Lissandra Dal Lago

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Prediction of venous thromboembolism in cancer patients

    Cihan Ay;Daniela Dunkler;Christine Marosi;Alexandru-Laurentiu Chiriac

  • Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    Manuela Schmidinger;Christoph C. Zielinski;Ursula M. Vogl;Andja Bojic

  • Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

    Gunter von Minckwitz;Andreas du Bois;Marcus Schmidt;Nicolai Maass

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

    Matti Aapro;David A Cameron;Ruth Pettengell;Julia Bohlius

  • A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

    Nathan I. Cherny;Richard Sullivan;U. Dafni;J. M. Kerst

  • Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

    Anna Sophie Berghoff;Barbara Kiesel;Georg Widhalm;Orsolya Rajky

  • ESMO-Magnitude of Clinical Benefit Scale version 1.1

    N.I. Cherny;U. Dafni;J. Bogaerts;N.J. Latino

  • D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study

    Cihan Ay;Rainer Vormittag;Daniela Dunkler;Ralph Simanek

  • Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Brigit Gruenberger;Dietmar Tamandl;Johannes Schueller;Werner Scheithauer

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

    Cihan Ay;Ralph Simanek;Rainer Vormittag;Daniela Dunkler

  • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

    Thomas Brodowicz;Maciej Krzakowski;Matjaz Zwitter;Valentina Tzekova

  • Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment.

    Wolfgang J. Köstler;Michael Hejna;Catharina Wenzel;Christoph C. Zielinski

  • High D-dimer levels are associated with poor prognosis in cancer patients

    Cihan Ay;Daniela Dunkler;Robert Pirker;Johannes Thaler

  • Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

    F. André;C. C. Zielinski

  • Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

    Giorgio V. Scagliotti;Thomas Brodowicz;Frances A. Shepherd;Christoph Zielinski

Frequent Co-Authors

Matthias Preusser
Matthias Preusser Medical University of Vienna
Michael Gnant
Michael Gnant Medical University of Vienna
Markus Raderer
Markus Raderer Medical University of Vienna
Ingrid Pabinger
Ingrid Pabinger Medical University of Vienna
Erika Jensen-Jarolim
Erika Jensen-Jarolim Medical University of Vienna
Peter Valent
Peter Valent Medical University of Vienna
Raimund Jakesz
Raimund Jakesz Medical University of Vienna
Ursula Wiedermann
Ursula Wiedermann Medical University of Vienna
Otto Scheiner
Otto Scheiner Medical University of Vienna
Werner Scheithauer
Werner Scheithauer Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean pursuing a traditional MD. There are a wide range of online degree programs that open doors to dynamic roles within healthcare. These alternative pathways offer flexibility and can be more affordable than traditional routes.

For those interested in healthcare leadership, consider cheap mha programs that prepare graduates for management roles in hospitals, clinics, and public health organizations. Nurses seeking advanced clinical or leadership roles may want to explore the most affordable dnp programs, which allow working professionals to earn a Doctor of Nursing Practice online.

Students drawn to the pharmacy field can look into online pharm d programs that offer the flexibility of distance learning while preparing candidates for careers as pharmacists. Additionally, the field of health information is expanding rapidly; the best online schools for high school students provide early exposure to health information management degrees, connecting students to crucial digital healthcare careers.

These online programs offer flexible scheduling and affordable tuition, making healthcare careers more accessible for students at all stages.

Best Scientists Citing Christoph C. Zielinski

Trending Scientists

Recently Published Articles